These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31015314)

  • 1. Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?
    Wong A; Billett A; Milne D
    Oncologist; 2019 Nov; 24(11):e1190-e1196. PubMed ID: 31015314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy.
    Levy D; Dhillon HM; Lomax A; Marthick M; McNeil C; Kao S; Lacey J
    Support Care Cancer; 2019 May; 27(5):1845-1852. PubMed ID: 30178142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
    Livingstone A; Dempsey K; Stockler MR; Howard K; Long GV; Carlino MS; Menzies AM; Morton RL
    BMC Cancer; 2021 Sep; 21(1):1014. PubMed ID: 34507552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Experiences of People Treated With Immunotherapies for Advanced Melanoma and Those Caring for Them: "Real-World" Data.
    Milne D; Hyatt A; Billett A; Gough K; Krishnasamy M
    Cancer Nurs; 2020; 43(2):E97-E104. PubMed ID: 30801266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to decision-making among late-stage melanoma patients: a multifactorial investigation.
    Garrett SB; Abramson CM; Rendle KA; Dohan D
    Support Care Cancer; 2019 Mar; 27(3):1059-1070. PubMed ID: 30136025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferences for Immunotherapy in Melanoma: A Systematic Review.
    Livingstone A; Agarwal A; Stockler MR; Menzies AM; Howard K; Morton RL
    Ann Surg Oncol; 2020 Feb; 27(2):571-584. PubMed ID: 31664622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Option Value of Innovative Treatments for Metastatic Melanoma.
    Thornton Snider J; Seabury S; Tebeka MG; Wu Y; Batt K
    Forum Health Econ Policy; 2018 Jun; 21(1):. PubMed ID: 30210050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists.
    Rocque GB; Rasool A; Williams BR; Wallace AS; Niranjan SJ; Halilova KI; Turkman YE; Ingram SA; Williams CP; Forero-Torres A; Smith T; Bhatia S; Knight SJ
    Oncologist; 2019 Oct; 24(10):1313-1321. PubMed ID: 30872466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing Hope and Risk Among Adolescent and Young Adult Cancer Patients with Late-Stage Cancer: A Qualitative Interview Study.
    Figueroa Gray M; Ludman EJ; Beatty T; Rosenberg AR; Wernli KJ
    J Adolesc Young Adult Oncol; 2018 Dec; 7(6):673-680. PubMed ID: 30096254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Decision-Making About Emergency and Planned Stoma Surgery for IBD: A Qualitative Exploration of Patient and Clinician Perspectives.
    Dibley L; Czuber-Dochan W; Wade T; Duncan J; Burch J; Warusavitarne J; Norton C; Artom M; O'Sullivan L; Verjee A; Cann D;
    Inflamm Bowel Dis; 2018 Jan; 24(2):235-246. PubMed ID: 29361098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
    J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family involvement in cancer treatment decision-making: A qualitative study of patient, family, and clinician attitudes and experiences.
    Laidsaar-Powell R; Butow P; Bu S; Charles C; Gafni A; Fisher A; Juraskova I
    Patient Educ Couns; 2016 Jul; 99(7):1146-1155. PubMed ID: 26873544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the factors impacting choice and quality of overnight private hospital stays and consumer perspectives on patient reported experience measures (PREMs) in Australia: a qualitative interview study.
    Verlis K; McCaffery K; Copp T; Dodd R; Laidsaar-Powell R; Nickel B
    J Patient Rep Outcomes; 2024 Jul; 8(1):75. PubMed ID: 39030440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
    Kamminga NCW; van der Veldt AAM; Wakkee M; van den Berge FR; van der Beek LAA; Joosen MCW; Joosse A; de Joode K; Nijsten TEC; Lugtenberg M
    BMC Cancer; 2024 May; 24(1):662. PubMed ID: 38816701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada.
    Cheung WY; White MK; Bayliss MS; Stroupe A; Lovley A; King-Kallimanis BL; Lasch K
    Support Care Cancer; 2019 Jan; 27(1):219-227. PubMed ID: 29934684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The views and experiences of older people with conservatively managed renal failure: a qualitative study of communication, information and decision-making.
    Selman LE; Bristowe K; Higginson IJ; Murtagh FEM
    BMC Nephrol; 2019 Feb; 20(1):38. PubMed ID: 30717686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
    McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
    Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy.
    McMullen S; Hess LM; Kim ES; Levy B; Mohamed M; Waterhouse D; Wozniak A; Goring S; Müller K; Muehlenbein C; Aggarwal H; Zhu Y; Oton AB; Ersek JL; Winfree KB
    Patient; 2019 Apr; 12(2):223-233. PubMed ID: 30128728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
    Tiu C; Wong A; Herschtal A; Mileshkin L
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):337-342. PubMed ID: 29498208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.